Compare NUVL & PRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | PRIM |
|---|---|---|
| Founded | 2017 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.7B |
| IPO Year | 2021 | 2006 |
| Metric | NUVL | PRIM |
|---|---|---|
| Price | $123.40 | $94.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 15 |
| Target Price | $134.75 | ★ $155.20 |
| AVG Volume (30 Days) | ★ 2.5M | 1.9M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.19% |
| EPS Growth | N/A | ★ 51.66 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.92 |
| Revenue Next Year | $1,239.49 | $8.80 |
| P/E Ratio | ★ N/A | $324.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.14 | $71.97 |
| 52 Week High | $123.62 | $205.50 |
| Indicator | NUVL | PRIM |
|---|---|---|
| Relative Strength Index (RSI) | 66.60 | 31.60 |
| Support Level | $97.71 | N/A |
| Resistance Level | N/A | $140.80 |
| Average True Range (ATR) | 4.37 | 9.00 |
| MACD | 1.97 | -0.90 |
| Stochastic Oscillator | 99.39 | 1.11 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.